Targeted Pulse Quiz: October 6

This week’s recap highlights several significant FDA developments. We also cover ongoing successes of pembrolizumab with chemotherapy in NSCLC.

Promising results from the anti–LAG-3/anti–PD-1 combo for melanoma, FDA approval of inavolisib for PIK3CA-mutant breast cancer, significant survival benefits from talazoparib and enzalutamide in prostate cancer, and the launch of the TWINPEAK trial for gastric cancers.

Cologuard Plus test receives FDA approval, understanding genomic profiling leads to advanced personalized care in breast cancer, and a new CAR T therapy is making waves in multiple myeloma.

Test your knowledge on the current pulse of oncology including FDA updates and breaking data with our Targeted Pulse Quiz.

Durcabtagene autoleucel shows high response rates in R/R multiple myeloma; olomorasib plus pembrolizumab demonstrates efficacy in KRAS G12C-mutated NSCLC; and the combination of talquetamab, daratumumab, and pomalidomide achieves durable responses. We also cover the FDA’s ODAC vote against checkpoint inhibitors for esophageal cancer.